Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorNIELAND, Kaspar
dc.contributor.authorLABBE, Antoine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSCHWEITZER, Cedric
ORCID: 0000-0002-2162-9479
IDREF: 133631583
dc.contributor.authorGICQUEL, Gaetan
dc.contributor.authorKLEINTJENS, Joris
dc.contributor.authorOSTAWAL, Amrita
dc.contributor.authorTREUR, Maarten
dc.contributor.authorFALVEY, Heather
dc.date.accessioned2021-08-23T09:51:26Z
dc.date.available2021-08-23T09:51:26Z
dc.date.issued2021-06-10
dc.identifier.issn1932-6203 (Electronic) 1932-6203 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/110189
dc.description.abstractEnOBJECTIVE: To investigate the cost-effectiveness of implementing iStent inject trabecular bypass stent (TBS) in conjunction with cataract surgery (Cat Sx) in patients with mild-to-moderate glaucoma from a societal perspective in France. The secondary objective was to explore the economic impact of iStent inject TBS in patients who comply to different degrees with their anti-glaucoma medications. METHODS: A previously published Markov model was adapted to estimate the cost-effectiveness of treatment with iStent inject TBS + Cat Sx versus Cat Sx alone over a lifetime time horizon in patients with mild-to-moderate open-angle glaucoma in France. Progression was modeled by health states reflecting increasing stages of vision loss. Disease progression was obtained from the two-year randomized clinical trial assessing safety and effectiveness of both interventions. French specific health-state utilities and costs were obtained through a targeted literature review. Model structure and inputs were validated by French ophthalmologists. Outcomes were expressed as incremental cost per quality-adjusted life-year (QALY) gained. The robustness of results was tested through sensitivity analyses. RESULTS: iStent inject TBS + Cat Sx reduced the number of medications needed and risk of blindness. Incremental cost and QALYs were euro75 and 0.065 leading to an incremental cost-effectiveness ratio (ICER) of euro1,154/QALY gained. ICER ranged from dominating for non-persistent patients to euro31,127 patients fully persistent with their medication regime. Results from one-way sensitivity analysis had a maximum ICER of euro29,000 when varying input parameters. iStent inject TBS + Cat Sx had an 86% chance of being cost-effective at a willingness-to-pay threshold of euro30,000 per QALY gained. CONCLUSION: Results demonstrate that iStent inject TBS + Cat Sx is a cost-effective intervention for intraocular pressure reduction when compared to Cat Sx alone in France.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enA cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France
dc.typeArticle de revueen_US
dc.identifier.doi10.1371/journal.pone.0252130en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34111130en_US
bordeaux.journalPLoS ONEen_US
bordeaux.pagee0252130en_US
bordeaux.volume16en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03324096
hal.version1
hal.date.transferred2021-08-23T09:51:30Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS%20ONE&rft.date=2021-06-10&rft.volume=16&rft.issue=6&rft.spage=e0252130&rft.epage=e0252130&rft.eissn=1932-6203%20(Electronic)%201932-6203%20(Linking)&rft.issn=1932-6203%20(Electronic)%201932-6203%20(Linking)&rft.au=NIELAND,%20Kaspar&LABBE,%20Antoine&SCHWEITZER,%20Cedric&GICQUEL,%20Gaetan&KLEINTJENS,%20Joris&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée